Sponsored by Legends Media*

Markets are moving fast, and I’ve been on fire with my tactical trade ideas this week—three straight ideas with 20%+ moves. Now, with Mpox news hitting headlines, there’s a stock on my radar that could be next. Check out the full details below…

TODAY’S TOP ALERT! 

Nasdaq: GOVX

👉  GOVX is TODAY’S #1 ALERT 👈

Hey there, Jeff Bishop here,

Yesterday’s inflation report gave us a nice correction from the big drawdown over the past month…

But stock futures show there’s no guarantee that will continue today.

It’s critical right now to seek stocks with a chance to surge regardless.

That’s exactly what I’ve done with my “tactical trade” ideas this week, which have been off to a fantastic start.

Monday’s idea surged as high as 27%, only to be outclassed by Tuesday’s idea which ripped 32%...

Yesterday’s idea on a small uranium stock also went on a tear:

That means my “tactical trade” ideas have gone 3-for-3 on soaring 20%+ or better on the day.

Why stop now?

This article from last week leads me to my next “tactical” idea:

There have been quite a few other “Mpox” stories out this month: The Telegraph, BBC, and World Health Organization, for examples.

Last Friday, Brazil confirmed its first case of this new Mpox variant.

With the WHO declaring Mpox a “global health emergency” in late 2024 — and renewing that declaration on February 27 — it goes without saying that there’s going to be plenty of R&D money going into companies pioneering vaccines and treatments for the disease…

That brings me to my “tactical trade” idea of the day:

Have a look at GeoVax Labs, Inc. (GOVX) on your favorite trading platform.

You’ll see that the stock climbed upwards of 20% to kick off the month, before pulling back a bit over the past week.

Yesterday, the stock gained 2.5% but tested as high as 9%.

But these moves are nothing for a company with a <$20M market cap…

Back in November, for instance, the stock had a 120% runup in a single week.

And with Mpox news continuing to break, I think GOVX is a stock that’s well worth watching.

That’s because the company has been developing a potentially game-changing vaccine candidate for Mpox (formerly known as monkeypox).

Its efforts have already made headlines, with Barron’s reporting about GOVX in August: “Mpox Worries Have Sent This Microcap Stock Sky High.” 

The article noted that the stock had jumped 40% shortly after the WHO’s announcement about the “public health emergency.”

You can read the company’s response to the recent Mpox news in this press release from February 27, but here’s the upshot:

“GeoVax is actively addressing these challenges with the development of GEO-MVA, its Mpox vaccine candidate. GeoVax has successfully manufactured and released the first clinical drug substance batch of GEO-MVA, with fill/finish and release of clinical product expected for mid-year, supporting the planned initiation of the clinical evaluation of GEO-MVA in the second half of this year.”

David Dodd, Chairman & CEO of GOVX, presented at a webinar on the topic last week. His talk was titled “MPOX 2025: Navigating the Global Public Health Emergency.”

I think investors may just be coming to terms with GOVX’s importance in this space, and that today is a great day to have the stock at the top of your radar.

👉  GOVX is TODAY’S #1 ALERT 👈

But the Mpox vaccine candidate isn’t GOVX’s only “shot on goal.” 

The company is pioneering the use of Modified Vaccinia Ankara (MVA) vector technology. This approach induces the production of virus-like particles (VLPs) directly within the vaccinated individual. 

It's like turning your body into its own vaccine factory, potentially leading to more effective immunizations. 

GOVX is using it to tackle a range of global health threats, from hemorrhagic fevers like Ebola and Marburg to emerging diseases like Zika and, of course, COVID-19. 

GEO-CM04S1 is the company’s attempt at a “next-generation COVID-19 vaccine” with features such as increased breadth of protection, longer durability, and protection for immune-compromised patients.

Last June, the company received a grant from the U.S. Department of Health and Human Services for a “a 10,000-participant, randomized, Phase 2b double-blinded study to compare the efficacy, safety, and immunogenicity of GEO-CM04S1 with a U.S. Food and Drug Administration (FDA)-approved mRNA COVID-19 vaccine.”

The direct award to GOVX is “approximately $24.3 million, which may increase to as much as $45 million.” [emphasis added]

Separately, the funding to support execution of the study is a whopping $343M.

GOVX is also venturing into oncology with therapies for solid tumors…

A Phase 1/2 trial evaluating its candidate Gedeptin at Stanford University, Emory University, and Thomas Jefferson University, recently closed to additional patient enrollment.

Gedeptin is an FDA-designated Orphan Drug, and the FDA provided funding for the trial as part of its orphan products clinical trial grants program.

The company says it is “advancing into a Phase 2 clinical trial [for Gedeptin] in 2025 . . . targeting first recurrent head and neck cancer.”

You can check out the company’s full pipeline here.

The company said last month that it “anticipates significant 2025 progress with catalyst-rich milestones across key programs.”

These include the anticipated beginning of patient enrollment for the HHS-funded COVID-19 trial discussed above.

For such a small stock, GOVX has generated considerable interest from analysts:

The D. Boral Capital price target is $18.00, so by my math, that’s an overall average price target of $14.60 — roughly 800% upside from its current price.

As you do your own research on GOVX, be sure to review the company’s very accessible website and this investor presentation released in January.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: GOVX is an up-and-coming player for a number of diseases, but with Mpox in the headlines and GOVX stock showing a history of price spikes on Mpox news, this is a stock I would keep a very close eye on today.

To Your Success,

Jeff Bishop